Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK KEAP1 dec exp |
| Therapy | Ceritinib |
| Indication/Tumor Type | lung cancer |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK KEAP1 dec exp | lung cancer | decreased response | Ceritinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Zykadia (ceritinib) in patient-derived lung cancer cells harboring EML4-ALK in culture (PMID: 28145866). | 28145866 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28145866) | KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. | Full reference... |